Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > You

<< Previous

Bullboard Posts

Next >>

Comment by Jshaw9on Mar 22, 2021 10:39am

106 Views

Post# 32849807

RE:RE:RE:RE:RE:RE:You

While you're reading, make sure you notice this little note they have on all their news releases... maybe all you hopefuls will benefit in the end, but the previous history of this company by never coming out with anything concrete and substantial, only big promises and dreams in the NR's... I got out at even and was tired of not seeing my money do anything. Considered myself lucky for not taking a loss.
not bashing, just hope none of you end up holding a bag in the end so good luck to you all

"The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain the Covid-19 (or SARS-2 Coronavirus) at this time."

<< Previous

Bullboard Posts

Next >>

New glaucoma treatment studied in a $3.4 billion market